Nivalis Therapeutics Inc. (NVLS) Given Buy Rating at HC Wainwright
Nivalis Therapeutics Inc. (NASDAQ:NVLS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Tuesday.
Other analysts also recently issued research reports about the company. Cowen and Company reiterated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st. Piper Jaffray Cos. reiterated a “buy” rating and set a $16.00 price target on shares of Nivalis Therapeutics in a research note on Tuesday, August 30th. Zacks Investment Research upgraded Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Thursday, October 20th. Stifel Nicolaus downgraded Nivalis Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $16.00 to $3.25 in a research note on Tuesday. Finally, Raymond James Financial Inc. downgraded Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $9.60.
Nivalis Therapeutics (NASDAQ:NVLS) traded down 59.7952% during mid-day trading on Tuesday, hitting $2.5128. The company had a trading volume of 3,279,286 shares. The company has a 50-day moving average price of $6.46 and a 200 day moving average price of $5.84. Nivalis Therapeutics has a 12 month low of $2.51 and a 12 month high of $9.46. The firm’s market capitalization is $39.06 million.
Nivalis Therapeutics (NASDAQ:NVLS) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. Equities analysts forecast that Nivalis Therapeutics will post ($2.10) EPS for the current fiscal year.
In other news, EVP David Malcom Rodman sold 5,820 shares of the business’s stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total value of $46,327.20. Following the completion of the transaction, the executive vice president now owns 18,056 shares of the company’s stock, valued at approximately $143,725.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.00% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in NVLS. Bank of New York Mellon Corp boosted its position in Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the last quarter. Spark Investment Management LLC acquired a new position in Nivalis Therapeutics during the third quarter worth $145,000. Paloma Partners Management Co acquired a new position in Nivalis Therapeutics during the second quarter worth $105,000. Endurant Capital Management LP boosted its position in Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in Nivalis Therapeutics during the third quarter worth $1,664,000. 79.26% of the stock is owned by institutional investors.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.